MOLSIDOMINE EG 4 mg, tablet 30 tablets
Active ingredients: Molsidomine
Commercialized according to BDPMDispensing in France: Prescription only
Tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MOLSIDOMINE EG 4 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium PVDC de 30 comprimé(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 21 Nov 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61544116CIP73555603CIP133400935556035Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MOLSIDOMINEcomprimé | 4 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.